By Suherman Candra Maholtra 
The global landscape of immunization was irrevocably altered on December 8, 2020, when the first clinically approved messenger RNA (mRNA) vaccine was administered to a patient outside of a trial setting. This milestone marked the culmination of decades of research and the beginning of a new era in biotechnology. According to epidemiological modeling published in The Lancet Infectious Diseases, these mRNA-based interventions prevented an estimated 14.4 million deaths worldwide within their first year of distribution. However, as the initial urgency of the COVID-19 pandemic transitions into a long-term public health strategy, the scientific community has identified significant structural and logistical hurdles that necessitate a second generation of vaccine technology. A multidisciplinary coalition from the Wyss Institute at Harvard University, the Dana-Farber Cancer Institute (DFCI), and several partner institutions has now introduced a potential successor: a DNA origami-based platform known as DoriVac.
The Evolution of Vaccine Technology: From mRNA Success to Modern Limitations
The success of the Pfizer-BioNTech and Moderna mRNA vaccines demonstrated that the human body could be turned into a localized factory for viral proteins, prompting the immune system to recognize and fight pathogens like SARS-CoV-2. Despite this triumph, the practical application of mRNA technology has revealed a series of persistent challenges. One of the primary concerns is the waning of immune protection. Data from various longitudinal studies have shown that neutralizing antibody titers often diminish significantly within six months of the primary series or booster doses, necessitating frequent re-vaccination.
Furthermore, the rapid evolution of the SARS-CoV-2 virus—characterized by the emergence of the Delta and Omicron lineages—has highlighted the difficulty of keeping pace with viral mutations. Because mRNA vaccines typically target the highly variable receptor-binding domain (RBD) of the spike protein, new variants can partially evade the immune defenses triggered by older vaccine versions. Beyond biological efficacy, the "cold chain" remains a formidable barrier to global health equity. mRNA-lipid nanoparticle (LNP) formulations are notoriously unstable, requiring ultra-low-temperature freezers (ranging from -80°C to -20°C) for storage and transport. This requirement has significantly hampered vaccine distribution in under-resourced regions, particularly in the Global South, where infrastructure for such stringent temperature control is often lacking.
The DoriVac Breakthrough: Engineering at the Nanoscale
To address these limitations, researchers led by William Shih, Ph.D., and Yang (Claire) Zeng, M.D., Ph.D., have turned to the field of DNA nanotechnology. Unlike traditional DNA vaccines that deliver genetic instructions to a cell’s nucleus, the DoriVac platform utilizes "DNA origami"—the folding of DNA strands into precise, three-dimensional geometric shapes.
The DoriVac structure functions as both a delivery vehicle (the vaccine) and a stimulant (the adjuvant). The platform is built from self-assembling DNA nanostructures that form tiny, rigid blocks. The precision of this engineering allows scientists to control the exact placement of molecules on the structure’s surface. On one face of the DNA origami square, the team attaches adjuvant molecules—specifically CpG motifs—at nanometer-scale intervals. On the opposite face, they attach antigens, such as peptides or proteins derived from a specific pathogen.
This spatial arrangement is critical. Research indicates that the immune system, particularly antigen-presenting cells like dendritic cells, responds most vigorously when immune-stimulating signals are presented at specific distances that mimic the natural patterns found on the surface of viruses and bacteria. By programming these distances at the molecular level, DoriVac can "supercharge" the immune recognition process in a way that unstructured vaccines cannot.
Chronology of Development: From Cancer Research to Antiviral Defense
The development of DoriVac followed a rigorous timeline that began in the field of oncology. In early 2024, the Wyss Institute and Dana-Farber teams first introduced DoriVac as a cancer immunotherapy tool. In preclinical trials involving tumor-bearing mice, the DNA origami structures were shown to provoke a significantly more robust T-cell response against cancer cells compared to vaccines where the antigens and adjuvants were delivered without the DNA scaffold.
As the COVID-19 pandemic persisted, the research team, led by Dr. Zeng—now the CEO and CTO of the spin-off DoriNano—pivoted to investigate whether this superior adjuvant activity could be applied to infectious diseases. Collaborating with Donald Ingber’s group at the Wyss Institute, the team expanded the platform’s scope to target some of the world’s most elusive viruses, including HIV and Ebola, alongside SARS-CoV-2.
The team focused on a specific region of the viral spike protein known as the Heptad Repeat 2 (HR2) domain. Unlike the receptor-binding domain, which mutates frequently, the HR2 domain is highly conserved across various coronaviruses and other viral families. By targeting this "Achilles’ heel," the researchers aimed to create a vaccine that remains effective even as the virus evolves into new variants.
Validating Efficacy: Mice and Human-on-a-Chip Models
The transition from theoretical design to biological validation involved a two-pronged testing strategy. First, the team conducted studies in mice, where the SARS-CoV-2 HR2 DoriVac vaccine demonstrated a broad activation of both humoral (antibody-producing) and cellular (T-cell) immunity. Specifically, the researchers observed a marked increase in the number of memory B cells and cytotoxic T cells—the "special forces" of the immune system responsible for long-term protection and the direct destruction of infected cells.
Recognizing that murine immune responses do not always translate perfectly to human biology—a gap that often leads to failure in late-stage clinical trials—the team utilized the Wyss Institute’s proprietary "Organ Chip" technology. This microfluidic system simulates a human lymph node in vitro, providing a more accurate preview of how human cells will react to a vaccine.
In the human Lymph Node Chip (human LN Chip) model, the DoriVac vaccine outperformed its origami-free counterparts. It successfully activated human dendritic cells and induced the production of inflammatory cytokines, which are essential for coordinating a systemic immune response. Furthermore, it stimulated the proliferation of CD4+ and CD8+ T cells, which are vital for establishing durable immunity in humans.
Comparative Data: DoriVac vs. mRNA-LNP Benchmarks
In a direct "head-to-head" comparison reported in Nature Biomedical Engineering, the researchers evaluated DoriVac against the industry-standard mRNA-LNP vaccines produced by Pfizer-BioNTech and Moderna. When mice were given a booster dose of either the DoriVac vaccine or an mRNA vaccine encoding the same SARS-CoV-2 spike protein, the results were striking: both platforms produced nearly identical levels of antiviral T-cell and B-cell activity.
However, the DoriVac platform demonstrated several advantages over the mRNA-LNP model:
- Thermal Stability: DNA origami structures are inherently more stable than the fragile lipid nanoparticles and mRNA strands. Preliminary data suggest that DoriVac vaccines could potentially be stored at room temperature or standard refrigeration, eliminating the need for a specialized cold chain.
- Manufacturing Simplicity: The self-assembling nature of DNA origami simplifies the production process. While LNP manufacturing involves complex microfluidic mixing and precise lipid-to-mRNA ratios that are difficult to scale uniformly, DoriVac structures assemble themselves based on the programmed sequence of the DNA strands.
- Safety Profile: Early safety assessments conducted by DoriNano have shown that the DNA origami platform is well-tolerated and lacks the off-target effects sometimes associated with the systemic distribution of lipid nanoparticles.
Official Responses and Strategic Implications
The implications of this research have been met with enthusiasm by the study’s lead authors. William Shih, Ph.D., emphasized the flexibility of the platform, stating that DoriVac provides an "unprecedented control over vaccine composition" and allows for the "programming of immune recognition" at a level of detail previously thought impossible.
Donald Ingber, M.D., Ph.D., highlighted the role of the Human Organ Chip technology in de-risking the development process. "The predictive capabilities of human LN Chips gave us an ideal testing ground," Ingber noted, suggesting that this convergence of nanotechnology and microfluidics could dramatically raise the success rates for new classes of vaccines.
From a global health perspective, the DoriVac platform represents a potential shift toward vaccine sovereignty for developing nations. Because the manufacturing process is less reliant on the proprietary and complex LNP technology held by a few major pharmaceutical companies, and because the end product is more stable, DoriVac could theoretically be produced and distributed more locally and equitably.
Future Outlook: A Universal Vaccine Chassis
The research published in Nature Biomedical Engineering is only the beginning for DNA origami vaccines. Ongoing clinical trials and preclinical studies are now exploring the platform’s utility for other infectious threats, including influenza, Respiratory Syncytial Virus (RSV), Zika, and tuberculosis.
As the world prepares for "Disease X"—the hypothetical next pandemic—the DoriVac platform offers a "chassis" that can be quickly reconfigured. By simply swapping out the antigen on the DNA square, scientists could potentially develop a new vaccine in a matter of weeks, mirroring the speed of mRNA development but with the added benefits of durability, stability, and enhanced immune activation.
While the road to widespread clinical use still requires large-scale human trials and regulatory approval, the data suggests that DNA origami could provide the necessary bridge between the high-speed innovation of the COVID-19 era and the long-term requirements of global infectious disease management. The fusion of nanotechnology, immunology, and microfluidics seen in the DoriVac project may well define the next decade of preventive medicine.
